Reversal of estrogen-resistance in murine mammary adenocarcinomas
From mouse mammary progestin-dependent (PD) adenocarcinomas induced with medroxyprogesterone acetate (MPA) we developed several in vivo lines that are maintained by subcutaneous syngeneic passages in MPA-treated mice and express estrogen (ER) and progesterone receptors (PR). Although most lines rema...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
1999
|
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 13814caa a22013577a 4500 | ||
|---|---|---|---|
| 001 | PAPER-19532 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518205053.0 | ||
| 008 | 190411s1999 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-0032981806 | |
| 024 | 7 | |2 cas |a Antineoplastic Agents, Hormonal; Drug Implants; Estradiol, 50-28-2; Medroxyprogesterone 17-Acetate, 71-58-9; Progestins; Receptors, Estrogen; Receptors, Progesterone | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 030 | |a BCTRD | ||
| 100 | 1 | |a Montecchia, M.F. | |
| 245 | 1 | 0 | |a Reversal of estrogen-resistance in murine mammary adenocarcinomas |
| 260 | |c 1999 | ||
| 270 | 1 | 0 | |m Lanari, C.; IBYME, Vuelta de Obligado 2490, 1428 Buenos Aires, Argentina |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Fisher, B., Redmond, C., Brown, A., Wolmark, N., Wittliff, J., Fisher, E.R., Treatment of primary breast cancer with chemotherapy and tamoxifen (1981) N Engl J Med, 305, pp. 1-6 | ||
| 504 | |a Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy (1992) Lancet, 339, pp. 1-15 | ||
| 504 | |a Muss, H.B., Endocrine therapy for advanced breast cancer: A review (1992) Breast Cancer Res Treat, 21, pp. 15-26 | ||
| 504 | |a Brunner, N., Clarke, R., Lippman, M.E., Dickson, R.B., Models for studying the progression from hormone-dependency to independency in human breast cancer (1990) Growth Regulation of Cancer, pp. 15-125. , Lippman ME, Dickson RB (eds). New York, Alan Liss | ||
| 504 | |a Ballare, C., Bravo, A.I., Laucella, S., Sorin, I., Cerdeiro, R., Loza, J., Souza Martinez, F., Mordoh, J., DNA synthesis in estrogen receptor-positive human breast cancer takes place preferentially in estrogen receptor-negative cells (1989) Cancer, 64, pp. 842-848 | ||
| 504 | |a Robertson, J.F.R., Oestrogen receptor: A stable phenotype in breast cancer (1996) Br J Cancer, 73, pp. 5-12 | ||
| 504 | |a Encarnación, C.A., Ciocca, D.R., McGuire, W.L., Clark, G.M., Fuqua, S.A.W., Osborne, C.K., Measurement of steroid hormone receptors in breast cancer patients on tamoxifen (1993) Breast Cancer Res Treat, 26, pp. 237-246 | ||
| 504 | |a Pakdel, F., Katzenellenbogen, B.S., Human estrogen receptor mutants with altered estrogen and antiestrogen ligand discrimination (1992) J Biol Chem, 267, pp. 3429-3437 | ||
| 504 | |a Mahfoudi, A., Roulet, E., Dauvois, S., Parker, M.G., Wahli, W., Specific mutations in the estrogen receptor change the properties of antiestrogens to full agonists (1995) Proc Natl Acad Sci USA, 92, pp. 4206-4210 | ||
| 504 | |a Jiang, S., Parker, C.J., Jordan, C.V., A model to describe how a point mutation of the estrogen receptor alters the structure function relationship of antiestrogens (1992) Breast Cancer Res Treat, 26, pp. 139-147 | ||
| 504 | |a Castles, C.G., Fuqua, S.A., Klotz, D.M., Hill, S.M., Expression of a constitutively active estrogen receptor variant in the estrogen receptor negative BT-20 human breast cancer cell line (1993) Cancer Res, 53, pp. 5934-5939 | ||
| 504 | |a Rea, D., Parker, M.J., Effects of an exon 5 variant of the estrogen receptor in MCF-7 breast cancer cells (1996) Cancer Res, 56, pp. 1556-1563 | ||
| 504 | |a Tonetti, D.A., Jordan, V.C., The role of estrogen mutations in tamoxifen-stimulated breast cancer (1997) J Steroid Biochem Molec Biol, 62, pp. 119-128 | ||
| 504 | |a Daffada, A.A.I., Johnston, S.R.D., Smith, I.E., Detre, S., King, N., Dowsett, M., Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer (1995) Cancer Res, 55, pp. 288-293 | ||
| 504 | |a Karnik, P.S., Kulkarni, S., Liu, X.P., Budd, G.T., Bukowski, R.M., Estrogen receptor mutations in tamoxifen-resistant breast cancer (1994) Cancer Res, 54, pp. 349-353 | ||
| 504 | |a Lupu, R., Cardillo, M., Cho, C., Harris, L., Hijazi, M., Perez, C., Rosenberg, K., Tang, C., The significance of heregulin in breast cancer tumor progression and drug resistance (1996) Breast Cancer Res Treat, 38, pp. 57-66 | ||
| 504 | |a Reiss, M., Barcellos-Hoff, M.H., Transforming growth factor β in breast cancer: A working hypothesis (1997) Breast Cancer Res Treat, 45, pp. 81-95 | ||
| 504 | |a Zhou, D.J., Casey, G., Cline, M.J., Amplification of human int-2 in breast cancers and squamous carcinomas (1988) Oncogene, 2, pp. 279-282 | ||
| 504 | |a Clarke, R., Brünner, N., Acquired estrogen independence and antiestrogen resistance in breast cancer. Estrogen receptor-driven phenotypes? (1996) Trends Endocrinol Metab, 7, pp. 291-301 | ||
| 504 | |a Edwards, D.P., Weigel, N.L., Nordeen, S.K., Beck, C.A., Modulators of cellular protein phosphorylation after the transactivation function of human progesterone receptor and the biological activity of progesterone antagonists (1993) Breast Cancer Res Treat, 27, pp. 41-56 | ||
| 504 | |a Sasano, H., Ozaki, M., Aromatase expression and its localization in human breast cancer (1997) J Steroid Biochem Mol Biol, 61, pp. 293-298 | ||
| 504 | |a Osborne, C.K., Fuqua, S.A.W., Mechanism of tamoxifen resistance (1994) Breast Cancer Res Treat, 32, pp. 49-55 | ||
| 504 | |a Burger, M.M., Moses, H.L., Mechanisms of growth factor and hormone insensitivity (1997) Int J Cancer, 73, pp. 461-463 | ||
| 504 | |a Lanari, C., Molinolo, A.A., Pasqualini, C.D., Induction of mammary adenocarcinomas by modroxyprogesterone aculate in BALB/c mice (1986) Cancer Letters, 33, pp. 215-223 | ||
| 504 | |a Molinolo, A.A., Lanari, C., Charreau, E.H., Sanjuan, N., Pasqualini, C.D., Mouse mammary tumors induced by medroxyprogesterone acetate: Immunochemistry and hormonal receptors (1987) J Natl Cancer Inst, 79, pp. 1341-1350 | ||
| 504 | |a Kordon, E., Molinolo, A.A., Pasqualini, C.D., Charreau, E.H., Pazos, P., Dran, G., Lanari, C., Progesterone induction of mammary carcinomas in BALB/c female mice. Correlation between hormone dependence and morphology (1993) Breast Cancer Res Treat, 28, pp. 29-39 | ||
| 504 | |a Kordon, E., Guerra, F., Molinolo, A.A., Elizalde, P., Charreau, E.H., Pasqualini, C.D., Montecchia, M.F., Lanari, C., Effect of sialoadenectomy on medroxyprogesterone acetate (MPA)-induced mammary carcinogenesis in BALB/c mice (1994) Int J Cancer, 59, pp. 196-203 | ||
| 504 | |a Kordon, E., Lanari, C., Molinolo, A.A., Elizalde, P., Charreau, E.H., Pasqualini, C.D., Estrogen inhibition of MPA-induced mouse mammary tumor transplants (1991) Int J Cancer, 49, pp. 900-905 | ||
| 504 | |a Satyaswaroop, P.G., Sivarajah, A., Zaino, R.J., Mortel, R., Hormonal control of growth of human endometrial carcinoma in the nude mouse model (1988) Progress in Cancer Res and Therapy, Vol 35. Hormones and Cancer 3, 35, pp. 430-435. , Bresciani F, King RJR, Lippman ME, Raynaud JP (eds). Raven Press, New York | ||
| 504 | |a Gottardis, M.M., Jordan, V.C., Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration (1988) Cancer Res, 48, pp. 5183-5187 | ||
| 504 | |a Osborne, K.C., Coronado, C., Allred, K., Wiebe, V., DeGregorio, M., Acquired tamoxifen resistance: Correlation with reduced breast tumor levels of tamoxifen and isomerization of tran-4-hydroxytasmoxifen (1991) J Natl Cancer Inst, 83, pp. 1477-1482 | ||
| 504 | |a Darbre, P.D., King, R.J.B., Interaction of different steroid hormones during progression of tumour cells to steroid autonomy (1987) Int J Cancer, 40, pp. 802-806 | ||
| 504 | |a Paik, S., Hartmann, D.P., Dickson, R.B., Lippmann, M.E., Antiestrogen resistance in ER positive breast cancer cells (1994) Breast Cancer Res Treat, 31, pp. 301-307 | ||
| 504 | |a Alt, F.W., Kellems, R.E., Bertino, J.R., Schimke, R.T., Selective multiplication of dihydrofolate reductase genes in methotrexate-resistant variants of cultured mouse cells (1978) J Biol Chem, 253, pp. 1357-1370 | ||
| 504 | |a Markopoulos, C., Berger, U., Wilson, P., Gazet, J.C., Coombes, R.C., Oestrogen receptor content of normal breast cells and breast carcinomas throughout the menstrual cycle (1988) Br J Med, 296, pp. 1349-1351 | ||
| 504 | |a Axelrod, D.M., Menendez-Botet, C.J., Kinne, D.W., Osborne, M.P., Levels of estrogen and progesterone receptor proteins in patients with breast cancer during various phases of menses (1988) Cancer Invest, 6, pp. 7-14 | ||
| 504 | |a Weimer, D.A., Donegan, W.L., Changes in estrogen and progesterone receptor content of primary breast carcinoma during the menstrual cycle (1987) Breast Cancer Res Treat, 10, pp. 273-278 | ||
| 520 | 3 | |a From mouse mammary progestin-dependent (PD) adenocarcinomas induced with medroxyprogesterone acetate (MPA) we developed several in vivo lines that are maintained by subcutaneous syngeneic passages in MPA-treated mice and express estrogen (ER) and progesterone receptors (PR). Although most lines remained PD, with time some progestin-independent (PI) variants arose. Both PD and PI tumors regress with estrogen treatment although estrogen-resistant variants may also arise. The object of this paper was to investigate the reversibility of estrogen-resistance and its possible relation with hormone receptor down-regulation. Tumor regression was induced in a progestin-independent tumor line (BET) by treatment with a 5 mg 17β-estradiol (E2) silastic pellet. One of the tumors started to grow disclosing an estrogen-resistant pattern of growth. This tumor line (BET-R) was transplanted into E2-treated and untreated animals (n = 4-6), selecting for the next passage tumors growing in treated animals. Seven new sublines were obtained at different passages by selecting for the next passage the tumors that had grown in untreated mice (BET-Ra-BET-Rg), until no tumors grew in E2-treated mice. ER and PR were measured by a ligand-binding, dextran-coated charcoal method using a single saturating point. From the seven sublines initiated, the first four proved to be reversible after 3-6 generation transplantation and the last three did not revert. A difference in PR expression between BET and BET-R (p < 0.05) was registered, but it did not correlate with the specific hormone behavior since two reverted lines had a pattern similar to that of BET and the other two were similar to BET-R. The expression of PR was higher in E2-treated mice (p < 0.05) and highly variable in the parental line. This led us to study the expression of PR at different stages of the estrous cycle. Higher levels of PR were observed in proestrous, estrous, and metestrous (p < 0.05) than in diestrous, and undetectable levels were found in ovariectomized mice. No differences in ER expression were detected during the estrous cycle. It can be concluded that under certain experimental conditions, estrogen-resistance is a reversible phenomenon. The experimental manipulation of hormone resistance may help develop strategies to modify the response to anti-hormones in humans. |l eng | |
| 536 | |a Detalles de la financiación: Fundación Alberto J. Roemmers | ||
| 536 | |a Detalles de la financiación: Consejo Nacional de Investigaciones Científicas y Técnicas, PIA: PMT.PICT 0446 | ||
| 536 | |a Detalles de la financiación: This work was supported by CONICET grant: PIA: PMT.PICT 0446, Fundación Sales, Fundación Roemmers, and Schering Argentina. We are also grateful to Dr. Gador Laboratories for supplying MPA. | ||
| 593 | |a Lab. of Hormonal Carcinogenesis, Inst. Biologia y Med. Exp. (IBYME), CONICET, Buenos Aires, Argentina | ||
| 593 | |a IBYME, Vuelta de Obligado 2490, 1428 Buenos Aires, Argentina | ||
| 690 | 1 | 0 | |a ESTROGENS |
| 690 | 1 | 0 | |a HORMONE INDEPENDENCE |
| 690 | 1 | 0 | |a HORMONE RESISTANCE |
| 690 | 1 | 0 | |a MAMMARY ADENOCARCINOMAS |
| 690 | 1 | 0 | |a MICE |
| 690 | 1 | 0 | |a REVERSIBILITY |
| 690 | 1 | 0 | |a ESTRADIOL |
| 690 | 1 | 0 | |a ESTROGEN |
| 690 | 1 | 0 | |a ESTROGEN RECEPTOR |
| 690 | 1 | 0 | |a GESTAGEN |
| 690 | 1 | 0 | |a HORMONE RECEPTOR |
| 690 | 1 | 0 | |a MEDROXYPROGESTERONE ACETATE |
| 690 | 1 | 0 | |a PROGESTERONE RECEPTOR |
| 690 | 1 | 0 | |a SILASTIC |
| 690 | 1 | 0 | |a ANIMAL EXPERIMENT |
| 690 | 1 | 0 | |a ANIMAL MODEL |
| 690 | 1 | 0 | |a ARTICLE |
| 690 | 1 | 0 | |a BREAST ADENOCARCINOMA |
| 690 | 1 | 0 | |a DRUG RESISTANCE |
| 690 | 1 | 0 | |a ESTROGEN THERAPY |
| 690 | 1 | 0 | |a ESTRUS CYCLE |
| 690 | 1 | 0 | |a HORMONE RESISTANCE |
| 690 | 1 | 0 | |a LIGAND BINDING |
| 690 | 1 | 0 | |a MOUSE |
| 690 | 1 | 0 | |a NONHUMAN |
| 690 | 1 | 0 | |a PRIORITY JOURNAL |
| 690 | 1 | 0 | |a PROTEIN EXPRESSION |
| 690 | 1 | 0 | |a RECEPTOR DENSITY |
| 690 | 1 | 0 | |a RECEPTOR DOWN REGULATION |
| 690 | 1 | 0 | |a TUMOR REGRESSION |
| 690 | 1 | 0 | |a ADENOCARCINOMA |
| 690 | 1 | 0 | |a ANIMALS |
| 690 | 1 | 0 | |a ANTINEOPLASTIC AGENTS, HORMONAL |
| 690 | 1 | 0 | |a CELL DIVISION |
| 690 | 1 | 0 | |a DRUG IMPLANTS |
| 690 | 1 | 0 | |a DRUG RESISTANCE, NEOPLASM |
| 690 | 1 | 0 | |a ESTRADIOL |
| 690 | 1 | 0 | |a FEMALE |
| 690 | 1 | 0 | |a MAMMARY NEOPLASMS, EXPERIMENTAL |
| 690 | 1 | 0 | |a MEDROXYPROGESTERONE 17-ACETATE |
| 690 | 1 | 0 | |a MICE |
| 690 | 1 | 0 | |a MICE, INBRED BALB C |
| 690 | 1 | 0 | |a PROGESTINS |
| 690 | 1 | 0 | |a RECEPTORS, ESTROGEN |
| 690 | 1 | 0 | |a RECEPTORS, PROGESTERONE |
| 700 | 1 | |a Molinolo, A. | |
| 700 | 1 | |a Lanari, C. | |
| 773 | 0 | |d 1999 |g v. 54 |h pp. 93-99 |k n. 2 |p Breast Cancer Res. Treat. |x 01676806 |t Breast Cancer Research and Treatment | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-0032981806&doi=10.1023%2fA%3a1006177619192&partnerID=40&md5=15c753eb329f024a3d46aa4383575db2 |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1023/A:1006177619192 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_01676806_v54_n2_p93_Montecchia |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_01676806_v54_n2_p93_Montecchia |y Registro en la Biblioteca Digital |
| 961 | |a paper_01676806_v54_n2_p93_Montecchia |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 80485 | ||